Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00

Zura Bio (NASDAQ:ZURA) had its price objective dropped by investment analysts at Oppenheimer from $16.00 to $15.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 172.73% from the stock’s previous close.

Several other analysts have also recently weighed in on the stock. Wedbush assumed coverage on shares of Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. Finally, Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a research note on Sunday, November 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

Zura Bio Stock Performance

NASDAQ ZURA opened at $5.50 on Friday. The stock has a market cap of $357.61 million, a P/E ratio of -5.19 and a beta of 0.18. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $7.44. The stock has a 50 day simple moving average of $6.17 and a two-hundred day simple moving average of $4.55.

Zura Bio (NASDAQ:ZURA) last posted its earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.31). Sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Insider Buying and Selling at Zura Bio

In other news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the acquisition, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.23% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP purchased a new position in Zura Bio in the 4th quarter worth about $872,000. XTX Topco Ltd bought a new stake in shares of Zura Bio in the fourth quarter worth $348,000. Suvretta Capital Management LLC increased its position in Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after acquiring an additional 94,110 shares during the last quarter. Quadrature Capital Ltd bought a new position in Zura Bio in the fourth quarter valued at about $192,000. Finally, Millennium Management LLC boosted its position in Zura Bio by 75.1% in the fourth quarter. Millennium Management LLC now owns 1,032,680 shares of the company’s stock worth $5,411,000 after purchasing an additional 442,980 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.